Rigel Pharmaceuticals Files 8-K Report
Ticker: RIGL · Form: 8-K · Filed: Dec 10, 2025 · CIK: 1034842
| Field | Detail |
|---|---|
| Company | Rigel Pharmaceuticals Inc (RIGL) |
| Form Type | 8-K |
| Filed Date | Dec 10, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, financials
TL;DR
Rigel Pharmaceuticals filed an 8-K on Dec 10th for events on Dec 7th. Standard disclosure.
AI Summary
On December 7, 2025, Rigel Pharmaceuticals, Inc. filed an 8-K report to disclose other events and financial statements/exhibits. The filing was made on December 10, 2025, and pertains to the company's operations as of December 7, 2025. Rigel Pharmaceuticals is incorporated in Delaware and headquartered in South San Francisco, California.
Why It Matters
This 8-K filing indicates a routine disclosure of events and financial information by Rigel Pharmaceuticals, Inc., providing transparency to investors about the company's status.
Risk Assessment
Risk Level: low — This filing is a routine 8-K for other events and financial statements, not indicating any specific material adverse events.
Key Players & Entities
- RIGEL PHARMACEUTICALS, INC. (company) — Registrant
- December 7, 2025 (date) — Date of earliest event reported
- December 10, 2025 (date) — Date of report
- South San Francisco, CA (location) — Principal executive offices location
FAQ
What is the primary purpose of this 8-K filing for Rigel Pharmaceuticals, Inc.?
The primary purpose of this 8-K filing is to report 'Other Events' and 'Financial Statements and Exhibits' as of December 7, 2025.
When was this 8-K report filed with the SEC?
This 8-K report was filed on December 10, 2025.
What is the principal executive office address for Rigel Pharmaceuticals, Inc.?
The principal executive offices are located at 611 Gateway Boulevard, Suite 900, South San Francisco, CA 94080.
In which state is Rigel Pharmaceuticals, Inc. incorporated?
Rigel Pharmaceuticals, Inc. is incorporated in Delaware.
What is the telephone number for Rigel Pharmaceuticals, Inc.?
The registrant's telephone number, including area code, is (650) 624-1100.
Filing Stats: 482 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2025-12-10 16:05:42
Key Financial Figures
- $0.001 — h Registered Common Stock, par value $0.001 per share RIGL The Nasdaq Stock Mar
Filing Documents
- tm2533140d1_8k.htm (8-K) — 24KB
- tm2533140d1_ex99-1.htm (EX-99.1) — 20KB
- tm2533140d1_ex99-1img01.jpg (GRAPHIC) — 4KB
- 0001104659-25-119976.txt ( ) — 217KB
- rigl-20251207.xsd (EX-101.SCH) — 3KB
- rigl-20251207_lab.xml (EX-101.LAB) — 33KB
- rigl-20251207_pre.xml (EX-101.PRE) — 22KB
- tm2533140d1_8k_htm.xml (XML) — 4KB
01. Other Events
Item 8.01. Other Events. On December 7, 2025, Rigel Pharmaceuticals, Inc. ("Rigel") announced certain data from its ongoing Phase 1b study evaluating R289 in lower-risk myelodysplastic syndrome. A copy of Rigel's press release, titled "Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition," is attached as Exhibit 99.1 to this report and is incorporated herein by reference.
01. Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Description 99.1 Press Release, dated December 7, 2025, titled "Rigel Presents Updated Data from the Ongoing Phase 1b Study Evaluating R289 in Patients with Lower-Risk MDS at the 67th ASH Annual Meeting and Exposition." 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: December 10, 2025 RIGEL PHARMACEUTICALS, INC. By: /s/ Raymond J.Furey Raymond J.Furey Executive Vice President, General Counsel, Chief Compliance Officer, and Corporate Secretary